STOCK TITAN

Autonomix Medical, Inc. - $AMIX STOCK NEWS

Welcome to our dedicated page for Autonomix Medical news (Ticker: $AMIX), a resource for investors and traders seeking the latest updates and insights on Autonomix Medical stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Autonomix Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Autonomix Medical's position in the market.

Rhea-AI Summary

Autonomix Medical announced the successful completion of a preclinical animal study demonstrating that targeted nerve ablation can significantly reduce tumor mass growth and metastases in pancreatic cancer. The study, involving mice injected with human pancreatic tumor cells, showed a 60% reduction in local invasion and a 40% decrease in liver metastases in the experimental group treated with peri-pancreatic neural ablation compared to the control group. CEO Lori Bisson highlighted these findings as supportive of the theory that nerve fibers contribute to cancer metastasis and emphasized potential future clinical applications. The company's technology aims to provide a more precise and effective alternative to current treatments for pancreatic cancer-related pain.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.91%
Tags
-
Rhea-AI Summary

Autonomix Medical (NASDAQ: AMIX), a company specializing in medical devices for nervous system diseases, will participate in the Virtual Investor Closing Bell Series on May 16, 2024, at 4:00 PM ET. CEO Lori Bisson will present a corporate overview and business outlook. The event will be live-streamed on the company's website, with an opportunity for live questions from investors. A replay will be available for 90 days post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
conferences
-
Rhea-AI Summary
Autonomix Medical, Inc. (NASDAQ: AMIX) has partnered with NoiseFigure Research, Inc. to enhance its ASIC microchip for human clinical testing and commercial production. The collaboration aims to revolutionize nerve system disease diagnosis and treatment. The proprietary ASIC technology promises superior nerve signal detection and localization, with 3000 times greater sensitivity than existing solutions. Autonomix's catheter-based technology targets neural signals associated with pain or disease, offering a more precise and effective alternative to current treatment methods. The initial focus is on addressing pancreatic cancer-related pain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.84%
Tags
none
Rhea-AI Summary
Autonomix Medical, Inc. (NASDAQ: AMIX) will be presenting at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on May 1, 2024. Lori Bisson, the CEO, will discuss recent corporate events in the medical device sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.42%
Tags
conferences
-
Rhea-AI Summary
Autonomix Medical, Inc. (NASDAQ: AMIX) announces the issuance of a U.S. patent covering proprietary catheter-based technology for the treatment of cancer-related pain. The company has a patent portfolio with over 100 patents, protecting technology targeting a $100 billion market opportunity. Autonomix is developing a two-fold technology that can detect problematic neural signals and ablate nerves in one procedure for pain management and other indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
none
-
Rhea-AI Summary
Autonomix Medical, Inc. completes successful preclinical study showcasing the potential of its catheter-based sensing technology for renal denervation. The technology aims to make procedures safer and more effective by accurately locating nerves around the renal artery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
Rhea-AI Summary
Autonomix Medical, Inc. (NASDAQ: AMIX) will present at the Virtual Investor Lunch Break: The Team Behind the AMIX Ticker event on April 11, 2024. The management team will discuss their roles in advancing innovative technologies for diagnosing and treating nervous system diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
conferences
-
Rhea-AI Summary
Autonomix Medical, Inc. (AMIX) CEO to present at MedInvest Biotech & Pharma Investor Conference on April 4th, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
conferences
-
Rhea-AI Summary
Autonomix Medical, Inc. (NASDAQ: AMIX) announces CEO Lori Bisson's presentation at the Benzinga Virtual Healthcare Summit 2024, showcasing the company's focus on innovative technologies for nervous system diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.37%
Tags
conferences
Rhea-AI Summary
Autonomix Medical, Inc. appoints Jennifer Cook as Chief Business Officer, bringing her extensive experience in business strategy and analysis to drive growth and value creation. With a proven track record in start-ups and medical technology brands, Cook's addition strengthens Autonomix's leadership team for future expansion and success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.16%
Tags
management
Autonomix Medical, Inc.

Nasdaq:AMIX

AMIX Rankings

AMIX Stock Data

43.92M
8.65M
46.2%
0.02%
0.19%
Medical Devices
Healthcare
Link
United States of America
THE WOODLANDS